Across TCGA pan-cancer cohorts, GBP6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GBP6 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GBP6 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated GBP6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, STAD, and PRAD are the cancer types where GBP6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	1.000	0.531	.016	14	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
PRAD	DFS	Median	All	0.617	0.886	.015	6	view →
SKCM	DFS	Median	III,IV	0.549	0.245	.017	5	view →
LUAD	DFS	Median	II,III,IV	1.000	0.527	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: GBP6 tumor-vs-normal RNA expression · all GBP6 data types